72.11.Z - Research and experimental development on biotechnology
20.42 - Manufacture of perfumes and toilet preparations
21.1 - Manufacture of basic pharmaceutical substances
21.2 - Manufacture of medicines and other pharmaceutical products
46.46 - Wholesale of pharmaceutical goods
47.73 - Dispensing chemist in specialised stores
58.11 - Book publishing
58.14 - Publishing of journals and periodicals
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 20,1 | -6,7 | -0,6 | 91,3 |
EBITDA | 20,2 | |||
Income tax | 0 | 0 | 0 | |
Equity capital | 26,1 | 19,4 | 18,8 | -3 |
Operating profit (EBIT) | 20,2 | |||
Assets | 32,8 | 19,7 | 19,1 | -2,9 |
Net profit (loss) | 20,1 | -6,7 | -0,6 | 91,3 |
Net income from sale | 0 | |||
Liabilities and provisions for liabilities | 6,8 | 0,4 | 0,4 | 0 |
Working assets | 0 | 0 | 0 | 0 |
Depreciation | 0 | |||
Basic operational activity income | 0 | 0 | 0 | |
% | % | % | p.p. | |
Profitability of capital | -34,6 | -3,1 | 31,5 | |
Equity capital to total assets | 79,4 | 98,2 | 98,2 | 0 |
Gross profit margin | 518 935,7 | 663 296,3 | ||
EBITDA Margin | 522 491 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane